{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:08:58Z","timestamp":1783415338247,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00213-025-06896-7","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:52:00Z","timestamp":1758329520000},"page":"1427-1435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lamotrigine is not associated with differential clinical outcomes in a real-world sample of patients with unipolar depression receiving ketamine or esketamine"],"prefix":"10.1007","volume":"243","author":[{"given":"Mia C.","family":"Santucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Nikayin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"issue":"8","key":"6896_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/da.22501","volume":"33","author":"CG Abdallah","year":"2016","unstructured":"Abdallah CG, Adams TG, Kelmendi B, Esterlis I, Sanacora G, Krystal JH (2016) Ketamine\u2019s mechanism of action: a path to rapid-acting antidepressants. Depress Anxiety 33(8):689\u2013697","journal-title":"Depress Anxiety"},{"issue":"4","key":"6896_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1503\/jpn.160175","volume":"42","author":"LR Aleksandrova","year":"2017","unstructured":"Aleksandrova LR, Phillips AG, Wang YT (2017) Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J Psychiatry Neurosci 42(4):222\u2013229","journal-title":"J Psychiatry Neurosci"},{"issue":"3","key":"6896_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/archpsyc.57.3.270","volume":"57","author":"A Anand","year":"2000","unstructured":"Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH (2000) Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 57(3):270\u2013276","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"6896_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351\u2013354","journal-title":"Biol Psychiatry"},{"issue":"11","key":"6896_CR5","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1177\/0269881111431751","volume":"26","author":"A Bruno","year":"2012","unstructured":"Bruno A, Mic\u00f2 U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D\u2019Arrigo C, Spina E, Zoccali RA, Muscatello MR (2012) Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 26(11):1456\u20131462","journal-title":"J Psychopharmacol"},{"issue":"4","key":"6896_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/PRA.0000000000000316","volume":"24","author":"LF Chan","year":"2018","unstructured":"Chan LF, Eu CL, Soh SY, Maniam T, Shahidii Kadir Z, Chong BTW, Loo JL, Sharip S, Wong VCW, Loo TH, Ng YP, Kahn DA (2018) Is ketamine the future clozapine for depression?? A case series and literature review on maintenance ketamine in treatment-resistant depression? with suicidal behavior. J Psychiatr Pract 24(4):279\u2013291","journal-title":"J Psychiatr Pract"},{"issue":"4","key":"6896_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ijnp\/pyab084","volume":"25","author":"G Chen","year":"2022","unstructured":"Chen G, Chen L, Zhang Y, Li X, Lane R, Lim P, Daly EJ, Furey ML, Fedgchin M, Popova V, Singh JB, Drevets WC (2022) Relationship between dissociation and antidepressant effects of Esketamine nasal spray in patients with treatment-resistant depression. Int J Neuropsychopharmacol 25(4):269\u2013279","journal-title":"Int J Neuropsychopharmacol"},{"issue":"10","key":"6896_CR8","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","volume":"22","author":"M Fedgchin","year":"2019","unstructured":"Fedgchin M, Trivedi M, Daly EJ, Melkote R, Lane R, Lim P, Vitagliano D, Blier P, Fava M, Liebowitz M, Ravindran A, Gaillard R, Ameele HVD, Preskorn S, Manji H, Hough D, Drevets WC, Singh JB (2019) Efficacy and safety of fixed-dose Esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 22(10):616\u2013630","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"6896_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41386-024-02002-1","volume":"50","author":"MV Foga\u00e7a","year":"2025","unstructured":"Foga\u00e7a MV, Daher F, Picciotto MR (2025) Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses. Neuropsychopharmacology 50(4):673\u2013684","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"6896_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/JCP.0000000000000316","volume":"35","author":"MA Frye","year":"2015","unstructured":"Frye MA, Blier P, Tye SJ (2015) Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol 35(3):334\u2013336","journal-title":"J Clin Psychopharmacol"},{"key":"6896_CR11","doi-asserted-by":"crossref","unstructured":"Fu DJ, Ionescu DF, Li X, Lane R, Lim P, Sanacora G, Hough D, Manji H, Drevets WC, Canuso CM (2020) Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry 81(3):19m13191","DOI":"10.4088\/JCP.19m13191"},{"key":"6896_CR12","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2165\/00003495-200363190-00009","volume":"63","author":"DR Goldsmith","year":"2003","unstructured":"Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM (2003) Lamotrigine: a review of its use in bipolar disorder. Drugs 63:2029\u20132050","journal-title":"Drugs"},{"issue":"5","key":"6896_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.amepre.2022.05.014","volume":"63","author":"RD Goodwin","year":"2022","unstructured":"Goodwin RD, Dierker LC, Wu M, Galea S, Hoven CW, Weinberger AH (2022) Trends in U.S. depression prevalence from 2015 to 2020: the widening treatment gap. Am J Prev Med 63(5):726\u2013733","journal-title":"Am J Prev Med"},{"issue":"4","key":"6896_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/JCP.0b013e3181e617a1","volume":"30","author":"JE Grant","year":"2010","unstructured":"Grant JE, Odlaug BL, Chamberlain SR, Kim SW (2010) A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J Clin Psychopharmacol 30(4):396\u2013403","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"6896_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","volume":"24","author":"DF Ionescu","year":"2021","unstructured":"Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets WC, Manji H, Canuso CM (2021) Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II). Int J Neuropsychopharmacol 24(1):22\u201331","journal-title":"Int J Neuropsychopharmacol"},{"key":"6896_CR16","doi-asserted-by":"publisher","unstructured":"Joseph B, Nunez NA, Kung S, Vande Voort JL, Pazdernik VK, Schak KM, Boehm SM, Carpenter B, Johnson EK, Malyshev G, Smits N, Adewunmi DO, Brown SK, Singh B (2023) Efficacy of ketamine with and without lamotrigine in treatment-resistant depression: a preliminary report. Pharmaceuticals (Basel) 16(8). https:\/\/doi.org\/10.3390\/ph16081164","DOI":"10.3390\/ph16081164"},{"issue":"2","key":"6896_CR17","first-page":"104","volume":"11","author":"M Khalkhali","year":"2016","unstructured":"Khalkhali M, Aram S, Zarrabi H, Kafie M, Heidarzadeh A (2016) Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran J Psychiatry 11(2):104\u2013114","journal-title":"Iran J Psychiatry"},{"issue":"3","key":"6896_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr., Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199\u2013214","journal-title":"Arch Gen Psychiatry"},{"key":"6896_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107494","volume":"208","author":"YF Li","year":"2020","unstructured":"Li YF (2020) A hypothesis of monoamine (5-HT) - glutamate\/GABA long neural circuit: aiming for fast-onset antidepressant discovery. Pharmacol Ther 208:107494","journal-title":"Pharmacol Ther"},{"issue":"1","key":"6896_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1017\/S1461145709000169","volume":"13","author":"SJ Mathew","year":"2010","unstructured":"Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS (2010) Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 13(1):71\u201382","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"6896_CR21","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, \u00c5sberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134(4):382\u2013389","journal-title":"Br J Psychiatry"},{"issue":"10","key":"6896_CR22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","volume":"170","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013a) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170(10):1134\u20131142","journal-title":"Am J Psychiatry"},{"issue":"4","key":"6896_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","volume":"74","author":"JW Murrough","year":"2013","unstructured":"Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV (2013b) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74(4):250\u2013256","journal-title":"Biol Psychiatry"},{"issue":"10","key":"6896_CR24","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","volume":"172","author":"DJ Newport","year":"2015","unstructured":"Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB (2015) Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172(10):950\u2013966","journal-title":"Am J Psychiatry"},{"issue":"16","key":"6896_CR25","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1523\/JNEUROSCI.4998-12.2013","volume":"33","author":"E Nosyreva","year":"2013","unstructured":"Nosyreva E, Szabla K, Autry AE, Ryazanov AG, Monteggia LM, Kavalali ET (2013) Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci 33(16):6990\u20137002","journal-title":"J Neurosci"},{"issue":"5","key":"6896_CR26","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.pharep.2017.04.021","volume":"69","author":"GZ R\u00e9us","year":"2017","unstructured":"R\u00e9us GZ, Matias BI, Maciel AL, Abelaira HM, Ign\u00e1cio ZM, de Moura AB, Matos D, Danielski LG, Petronilho F, Carvalho AF, Quevedo J (2017) Mechanism of synergistic action on behavior, oxidative stress and inflammation following co-treatment with ketamine and different antidepressant classes. Pharmacol Rep 69(5):1094\u20131102","journal-title":"Pharmacol Rep"},{"key":"6896_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ph13060116","author":"VL Ruberto","year":"2020","unstructured":"Ruberto VL, Jha MK, Murrough JW (2020) Pharmacological treatments for patients with treatment-resistant depression. Pharmaceuticals (Basel)13(6):116. https:\/\/doi.org\/10.3390\/ph13060116","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"6896_CR28","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R (2003) The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54(5):573\u2013583","journal-title":"Biol Psychiatry"},{"key":"6896_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2013.10.036","volume":"155","author":"PR Shiroma","year":"2014","unstructured":"Shiroma PR, Johns B, Kuskowski M, Wels J, Thuras P, Albott CS, Lim KO (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 155:123\u2013129","journal-title":"J Affect Disord"},{"issue":"2","key":"6896_CR30","first-page":"141","volume":"332","author":"GE Simon","year":"2024","unstructured":"Simon GE, Moise N, Mohr DC (2024) Manage Depress Adults: Rev Jama 332(2):141\u2013152","journal-title":"Manage Depress Adults: Rev Jama"},{"issue":"5","key":"6896_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/JCP.0000000000001898","volume":"44","author":"B Singh","year":"2024","unstructured":"Singh B (2024) Ketamine and esketamine for depression in daily practice: opportunities and challenges. J Clin Psychopharmacol 44(5):451\u2013455","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"6896_CR32","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","volume":"173","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC (2016) A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173(8):816\u2013826","journal-title":"Am J Psychiatry"},{"issue":"10","key":"6896_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/ijnp\/pyab039","volume":"24","author":"JKE Veraart","year":"2021","unstructured":"Veraart JKE, Smith-Apeldoorn SY, Bakker IM, Visser BAE, Kamphuis J, Schoevers RA, Touw DJ (2021) Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review. Int J Neuropsychopharmacol 24(10):808\u2013831","journal-title":"Int J Neuropsychopharmacol"},{"key":"6896_CR34","doi-asserted-by":"crossref","unstructured":"Wilkinson ST, Katz RB, Toprak M, Webler R, Ostroff RB, Sanacora G (2018) Acute and longer-term outcomes using Ketamine as a clinical treatment at the Yale Psychiatric Hospital. J Clin Psychiatry 79(4):17m11731","DOI":"10.4088\/JCP.17m11731"},{"issue":"4","key":"6896_CR35","first-page":"645","volume":"11","author":"A Wilkowska","year":"2022","unstructured":"Wilkowska A, Wiglusz MS, Jakuszkowiak-Wojten K, Cuba\u0142a WJ (2022) Ketamine and Lamotrigine combination in Psychopharmacology. Syst Rev Cells 11(4):645","journal-title":"Syst Rev Cells"},{"issue":"11","key":"6896_CR36","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.biopsych.2021.03.014","volume":"89","author":"H Wu","year":"2021","unstructured":"Wu H, Savalia NK, Kwan AC (2021) Ketamine for a boost of neural plasticity: how, but also when?? Biol Psychiatry 89(11):1030\u20131032","journal-title":"Biol Psychiatry"},{"issue":"8","key":"6896_CR37","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856\u2013864","journal-title":"Arch Gen Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06896-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-025-06896-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-025-06896-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:50:28Z","timestamp":1782924628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-025-06896-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["6896"],"URL":"https:\/\/doi.org\/10.1007\/s00213-025-06896-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Wilkinson reports having received contract research funding from Oui Therapeutics and consulting fees from LivaNova and Mind Medicine, all outside the submitted work. All other authors report no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This analysis of existing clinical data was judged exempt of full approval by the Yale School of Medicine IRB (HIC #2000029188).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The Yale Institutional Review Board (IRB) approved this study and waived informed consent per the Common Rule.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The Yale Institutional Review Board (IRB) approved this study and waived informed consent per the Common Rule.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Dr. Wilkinson reports receiving contract research funding for the conduct of clinical trials (administered through Yale University) from Oui Therapeutics; he also reports consulting for Mind Medicine, Sooma Medical, and Neumora Therapeutics. The other authors report no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}